Abstract
Introduction
This study aimed to illustrate the efficacy of the combination of lens extraction, trabeculectomy, and anterior vitrectomy in patients with secondary angle-closure glaucoma (ACG) with autosomal recessive bestrophinopathy or Best vitelliform macular dystrophy.
Methods
This is a retrospective self-controlled case series study. Five patients undergoing a single trabeculectomy in one eye and triple surgery in the other eye were enrolled. All patients underwent a complete ophthalmic examination that included best-corrected visual acuity (BCVA), intraocular pressure (IOP), ultrasound biomicroscopy, and static gonioscopy. Multimodal fundus imaging was performed, including color fundus photography, fundus autofluorescence, and optical coherence tomography. Genetic testing was also analyzed.
Results
Among the 10 eyes, the mean IOP was 31.4 ± 4.7 mmHg before surgery. The mean axial length (AL) was 21.53 mm and the anterior chamber depth (ACD) was 2.31 mm. There were no statistically significant differences in preoperative IOP, BCVA, ACD, and AL between the two groups (all P > 0.05). The mean follow-up time was 64.0 months. All five eyes with a single trabeculectomy developed malignant glaucoma (MG). No complications were found in the other five eyes with triple surgery, and the anterior chamber was deepened and stable after surgery until the last visit. The mean IOP at the last visit was normalized to 16 mmHg without using any medications.
Conclusions
Triple surgery is superior to single trabeculectomy for patients with ACG and BEST1 mutation, effectively bypassing MG complications. The vitreous may play a vital role in the mechanism of ACG in those patients and the high incidence of MG after filtering surgery.
Similar content being viewed by others
![](https://media.springernature.com/w215h120/springer-static/image/art%3A10.1007%2Fs10792-017-0797-7/MediaObjects/10792_2017_797_Fig1_HTML.gif)
Avoid common mistakes on your manuscript.
Why carry out this study? |
BEST1-associated retinopathy, especially for autosomal recessive bestrophinopathy, is often characterized as hyperopia, short axial length, and a high risk of angle-closure glaucoma. |
Younger onset age, being refractory to intraocular pressure (IOP) control, and 100% penetrance of malignant glaucoma after trabeculectomy make it a huge challenge in the management of refractory glaucoma in patients with Best disease. |
The purpose of this study is to compare the surgical outcome of triple surgery and single trabeculectomy in each patient with Best disease. |
What was learned from the study? |
The triple surgery, Phaco + IOL implantation–trabeculectomy–anterior pars plana vitrectomy (PPV), yielded excellent results in lowering IOP, maintaining the visual function, deepening the anterior chamber, and avoiding the complication of malignant glaucoma. |
The resolution of malignant glaucoma can be achieved by the surgery of phacoemulsification–IOL implantation–anterior PPV with successful lowering of IOP and reforming of the anterior chamber. |
The vitreous may play a vital role in the mechanism of angle-closure glaucoma in patients with Best disease. |
Introduction
Autosomal recessive bestrophinopathy (ARB), with homozygous or compound heterozygous sequence variants in BEST1, was first recognized by Burgess et al. [1] in 2008, with a high risk of angle-closure glaucoma (ACG). Angle closure with or without glaucoma was reported to affect around 29–71.4% of patients with ARB, the rate of which was much higher in Chinese patients [1,2,3,4]. The cause behind the simultaneous occurrence of ACG in BEST1-associated retinopathy, referred to as bestrophinopathies [5], including ARB and Best vitelliform macular dystrophy (BVMD), had not yet been elucidated.
Yttrium–aluminum–garnet laser peripheral iridotomy alone was not enough to reduce intraocular pressure (IOP) in patients with ARB with narrow anterior chamber [2]. Most reports agreed that a cataract extraction also failed to open the anterior chamber angle to a sufficient degree so that IOP was still high [2, 6, 7], despite a single case with controlled IOP, but required continued use of two topical medications after lens extraction [8]. Zhong et al. [7] also reported a unique case of a 26-year-old woman diagnosed with ARB and ACG without any improvement of the anterior structure by combined phacoemulsification, intraocular lens implantation, and goniosynechialysis, but benefit from additional low-dose transscleral cyclophotocoagulation (TCP) that ends with a lower IOP and a deepened anterior chamber in both eyes. The authors analyzed the reason for success: anterior vitreous liquefaction generated by post-TCP inflammation subsequently decreased vitreous integrity, absorbed the force from choroidal expansion, and increased flow conductivity through the vitreous cavity [7]. It indicated that the vitreous is intimately involved in the pathogenesis of the shallow anterior chamber in those patients. In addition to the younger age, solid and unliquefied vitreous presumably induce high posterior pressure, which is also confirmed during the surgery (personal perspective). The forward force potentially accelerates the development of narrow anterior chamber and even complete angle closure. This assumption is strengthened by our observation of 100% surgical success rate after triple surgery, while 100% penetration to MG after trabeculectomy alone inevitably increases the pressure gradient between the anterior and posterior segments. It is hereby especially emphasized that removal of the anterior vitreous is an indispensable procedure for patients with ACG and BEST1 mutation.
Malignant glaucoma is a serious complication after glaucoma filtering surgery, often with elevated IOP, but may also present with normal IOP, given the presence of an alternative aqueous outflow pathway. Although the exact mechanism of MG is not fully understood and may be multifactorial, the principle of management was clear: eliminate the pressure gradient between anatomic compartments and introduce communication between the posterior and anterior segments of the eye. The role of choroidal expansion has also been described [11]. In the present study, all five eyes with MG after trabeculectomy alone did not respond to medical management, including antiglaucoma medications and strong cycloplegics. It is reported that 14–50% of MG can be resolved with only medical therapy [12, 13]. The resolution of MG was finally achieved by the following surgery of phacoemulsification–IOL implantation–anterior PPV with successful lowering IOP and reforming of the anterior chamber. Our results provided an effective treatment algorithm for refractory MG in patients with BEST1 mutation. It showed that vitrectomy was required in those cases, potentially relieving the peripheral vitreous pressure, restoring the orientation of the ciliary body, and deepening the anterior chamber. Even the five eyes that experienced MG after trabeculectomy and following secondary surgery also achieved a good outcome compared to the other eyes that succeeded by triple surgery for the first time. A combined approach to simultaneously address all conditions would be advantageous to patients in terms of reduced costs and potentially faster visual recovery.
A single case (PPV + glaucoma drainage implant) without lens extraction shown by Low et al. [6] achieved a good outcome. However, clear lens/cataract extraction and IOL implantation were performed in all eyes in the present study. Removing the lens may largely deepen the anterior chamber and potentially reopen the angle, which is definitely beneficial to maintain the physiologic trabecular aqueous outflow since the filtering pathway is possibly no longer functional during their subsequent long life. We also encountered a case with a very early phase of ACG (not shown in this study) that underwent phacoemulsification, IOL implantation–goniosynechialysis–anterior PPV (without trabeculectomy), ending with deep anterior chamber and normal IOP. However, the therapeutic role of lens/cataract extraction in patients with ACG and BEST1 mutation needs to be clarified in future studies.
Young patients with angle closure are very rare [14]. Recently, Gao et al. [15] reviewed a large number of Chinese patients with ACG from 15-year records in a single center. The etiologies other than primary ACG could be identified in a large number of cases (67.4%). More comprehensive examinations are needed, especially fundus examinations, to exclude any secondary causes. Even with patients with ACG older than 40 years, especially combined with a fundus lesion such as “macular edema” in OCT, the differential diagnosis of ARB or BVMD with age-related macular degeneration and chorioretinitis can be challenging. Genetic analysis should be performed in suspect cases.
The application of mitomycin C during trabeculectomy remains the gold standard for glaucoma surgery, especially in China, since Asian patients appear to have a greater scarring response and are more susceptible to bleb failure compared to Caucasian patients [16]. The dose and duration of mitomycin C of 0.4 mg/ml and 2–3 min is very common in China [17]. Increasing the exposure time of mitomycin C can be adapted for younger patients who are known to have a greater wound healing capacity. In general, the surgical outcome can be influenced by the dose of mitomycin C, with higher rates of hypotony after higher concentration or/and duration. However, this complication was not found in any of our patients. Compared to our study, Zhong et al. applied a lower concentration of mitomycin C and a shorter exposure time which may indicate that the failure of single trabeculectomy in patients with ARB may not be related to mitomycin C dosing.
Limitations of our study should be discussed. First of all, there were two patients who underwent trabeculectomy at other local hospitals, so one may be concerned that the surgical outcome is influenced by the different levels of glaucoma specialists. However, trabeculectomy was also performed at the local tertiary eye center on these two patients, and according to the medical record, surgical procedures, including mitomycin C dose, were also similar to those of our hospital. Previous studies showed that the results of trabeculectomy performed by residents or trainees can also have a high success rate [18, 19]. We believed that the failure after single trabeculectomy in patients with ARB may not be affected by the different surgeons. Second, there was a possibility of bias between two eyes in each patient since trabeculectomy was always performed first in the eyes with usually earlier onset of ACG than in the other eyes, even though there were no significant differences in all ocular parameters between those two groups. Third, the follow-up time of patients was variable, and only two patients had a long-term follow-up after triple surgery. Long-term observations in those eyes with triple surgery should be addressed. Fourth, the EOG was not performed on all patients. However, multimodal imaging and genetic analysis can also support the diagnosis. The clinical diagnosis of ARB was also confirmed in one patient without genetic testing by a panel of retinal specialists. Fifth, the number of cases was relatively small. The condition in which the secondary ACG and ARB combined is very rare. In addition to that, the strict criteria that met the self-controlled study design also limited the number of enrollees. Sixth, the natural retrospective designs lead to a lack of preoperative and postoperative anterior segment photographs of the anterior chamber.
Conclusions
This self-controlled series study clearly showed that triple surgery is superior to single trabeculectomy for patients with ACG and BEST1 mutation in terms of IOP control, maintenance of visual function, and deepened anterior chamber, effectively bypassing the complication of MG. The role of the vitreous is complicated in the mechanism of ACG and the high incidence of MG after filtering surgery, together with the younger age, short AL, and shallow anterior chamber. Trabeculectomy was not a contraindication but is strongly recommended in combination with removal of the anterior vitreous in the management of patients with ACG with BEST1 mutation. MG can be successfully managed by appropriate and timely interventions.
References
Burgess R, Millar ID, Leroy BP, et al. Biallelic mutation of BEST1 causes a distinct retinopathy in humans. Am J Hum Genet. 2008;82(1):19–31.
Boon CJ, van den Born LI, Visser L, et al. Autosomal recessive bestrophinopathy: differential diagnosis and treatment options. Ophthalmology. 2013;120(4):809–20.
Luo J, Lin M, Guo X, et al. Novel BEST1 mutations and special clinical characteristics of autosomal recessive bestrophinopathy in Chinese patients. Acta Ophthalmol. 2019;97(3):247–59.
Casalino G, Khan KN, Armengol M, et al. Autosomal recessive bestrophinopathy: clinical features, natural history, and genetic findings in preparation for clinical trials. Ophthalmology. 2021;128(5):706–18.
Xuan Y, Zhang Y, Zong Y, et al. The clinical features and genetic spectrum of a large cohort of Chinese patients with vitelliform macular dystrophies. Am J Ophthalmol. 2020;216:69–79.
Low S, Mohamed R, Davidson A, et al. A new paradigm for delivering personalised care: integrating genetics with surgical interventions in BEST1 mutations. Eye (Lond). 2020;34(3):577–83.
Shi Y, Tian J, Han Y, Oatts J, Wang N. Pathogenic role of the vitreous in angle-closure glaucoma with autosomal recessive bestrophinopathy: a case report. BMC Ophthalmol. 2020;20(1):271.
Crowley C, Paterson R, Lamey T, et al. Autosomal recessive bestrophinopathy associated with angle-closure glaucoma. Doc Ophthalmol. 2014;129(1):57–63.
Zhong Y, Guo X, **ao H, et al. Flat anterior chamber after trabeculectomy in secondary angle-closure glaucoma with BEST1 gene mutation: case series. PLoS ONE. 2017;12(1):e0169395.
Mohler CW, Fine SL. Long-term evaluation of patients with Best’s vitelliform dystrophy. Ophthalmology. 1981;88(7):688–92.
Quigley HA, Friedman DS, Congdon NG. Possible mechanisms of primary angle-closure and malignant glaucoma. J Glaucoma. 2003;12(2):167–80.
Dave P, Senthil S, Rao HL, Garudadri CS. Treatment outcomes in malignant glaucoma. Ophthalmology. 2013;120(5):984–90.
Simmons RJ. Malignant glaucoma. Br J Ophthalmol. 1972;56(3):263–72.
Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121(11):2081–90.
Gao F, Wang J, Chen J, Wang X, Chen Y, Sun X. Etiologies and clinical characteristics of young patients with angle-closure glaucoma: a 15-year single-center retrospective study. Graefes Arch Clin Exp Ophthalmol. 2021;259(8):2379–87.
Wong TT, Khaw PT, Aung T, et al. The Singapore 5-fluorouracil trabeculectomy study: effects on intraocular pressure control and disease progression at 3 years. Ophthalmology. 2009;116(2):175–84.
Do JL, Xu BY, Wong B, et al. A randomized controlled trial comparing subconjunctival injection to direct scleral application of mitomycin C in trabeculectomy. Am J Ophthalmol. 2020;220:45–52.
Chan CK, Lee S, Sangani P, Lin LW, Lin MS, Lin SC. Primary trabeculectomy surgery performed by residents at a county hospital. J Glaucoma. 2007;16(1):52–6.
de Leon JMS, Pionela CMG. Outcomes of primary trabeculectomy with mitomycin-C for primary angle closure glaucoma among supervised trainees in a tertiary eye center in Manila. Int Ophthalmol. 2021;41(5):1643–50.
Acknowledgements
Funding
This project, and the journal’s Rapid Service Fee, were supported by Youth Talent Program from Bei**g Tongren Hospital, Capital Medical University.
Authorship
All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.
Author Contributions
**n Tang contributed to the conception and design of the study. Material preparation, data collection, and analysis were performed by Yuxin Fang, **aoming Duan, Lin Chen, Jie Shi (genetic testing), and Yang Li. Parts of imaging were supplied by Jie Liu, Yunxiao Sun, and ** Wang. The first draft of the manuscript was written by Yuxin Fang and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.
Disclosures
Yuxin Fang, **aoming Duan, Lin Chen, Jie Shi, Jie Liu, Yunxiao Sun, ** Wang, Yang Li and **n Tang confirm that they have no competing interests to declare.
Compliance with Ethics Guidelines
This study was carried out in accordance with the principles of the Declaration of Helsinki. The approval was granted by the Ethics Committee of the Bei**g Tongren Eye Center. Informed consent was obtained from all individual participants included in the study.
Data Availability
All data generated or analyzed during this study are included in this article. Further inquiries can be directed to the corresponding author.
Author information
Authors and Affiliations
Corresponding author
Additional information
Yuxin Fang and **aoming Duan contributed equally to the work presented here and should therefore be regarded as equivalent authors.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
About this article
Cite this article
Fang, Y., Duan, X., Chen, L. et al. Combination of Trabeculectomy and Primary Pars Plana Vitrectomy in the Successful Treatment of Angle-Closure Glaucoma with BEST1 Mutations: Self-Controlled Case Series. Ophthalmol Ther 11, 2271–2284 (2022). https://doi.org/10.1007/s40123-022-00580-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40123-022-00580-1